Short-term somatostatin infusion affects T lymphocyte responsiveness in humans

Malec, P; Zeman, Krzysztof; Markiewicz, K; Tchórzewski, H; Nowak, Zofia; Baj, Zbigniew

doi:10.1016/0162-3109(89)90007-6

Cited by 43 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In human PBMCs, inhibition of proliferation of mitogen-activated lymphocytes has been reported (20,41,42), although contrasting results have also been obtained with enriched lymphocyte fractions (43) and with a lymphoid cell line (22). In the latter studies proliferation could be stimulated by SS.…”

Section: Discussionmentioning

confidence: 81%

“…Further studies will have to elucidate this issue. A number of studies have shown functional effects of SS on human lymphocytes (6,20,41,42), providing evidence for the presence of functional sst on these cells. Corroborating our data, sst 3 was recently shown to be present in human enriched lymphocyte fractions, which also contained functional SS-binding sites (43).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets

Lichtenauer-Kaligis

Dalm

Oomen

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: Somatostatin (SS)-binding sites have been demonstrated in human lymphoid tissues and peripheral blood cells. However, not much is known with respect to the SS receptor subtype (sst) expression pattern and the expression of SS itself in the immune system. Objective: The aim of this study was to evaluate the mRNA expression of the five known sst (sst 1 -5 ) in peripheral blood mononuclear cell (sub)populations. Moreover, the expression of the mRNAs encoding SS and the SS-like peptide cortistatin (CST) in immune cell subsets was studied. Methods: RT-PCR and quantitative PCR were performed to evaluate sst, SS and CST mRNA expression in cells in the basal or activated state. Fluorescence-activated cell sorter (FACS) analysis using fluorescent SS was performed to visualize sst protein on cell membranes. Results: B-and T-lymphocytes selectively expressed sst 3 mRNA. sst 3 expression in B-lymphocytes was significantly lower compared with T-lymphocytes. Unstimulated, freshly isolated monocytes did not express any sst mRNA. Upon activation, monocytes selectively expressed sst 2 mRNA, whereas T-lymphocyte activation upregulated sst 3 expression. sst 2 mRNA expression on monocytes was confirmed by FACS analysis. B-and T-lymphocytes did not express SS mRNA, while both cell types expressed CST mRNA. CST mRNA expression was downregulated following T-lymphocyte activation. Conclusion: We demonstrate for the first time unequivocally that human peripheral blood B-and T-lymphocytes selectively express sst 3 , whereas monocytes do not express sst. However, upon activation, monocytes are induced to express sst 2A . No expression of SS mRNA was detected in any cell type, whereas all cell types expressed CST mRNA. The differential expression of sst and CST mRNA in lymphocytes and monocytes suggests a functional significance for the CST -sst interaction in immune cells, but further studies should be performed to evaluate the significance of sst and CST in these cells.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets

Lichtenauer-Kaligis

Dalm

Oomen

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…17,28,29, 45 The inhibitory effects of VIP and SMS on these lymphocytes are mediated by speci c receptors, not by cytotoxicity. [46][47][48] VIP has both pro-and anti-in ammatory effects on intestinal T-cells and macrophages, inducing IL-5 release and inhibiting macrophage adherence.…”

mentioning

confidence: 99%

Somatostatin in inflammatory bowel disease

Bergeijk

Wilson

1997

Mediators of Inflammation

View full text Add to dashboard Cite

Intestinal in ammation is controlled by various immunomodulating cells, interacting by molecular mediators. Neuropeptides, released by enteric nerve cells and neuroendocrine mucosa cells, are able to affect several aspects of the general and intestinal immune system, with both pro-as well as anti-in ammatory activities. In in ammatory bowel disease (IBD) there is both morphological as well as ex perimental evidence for involvement of neuropeptides in the pathogenesis. Somatostatin is the main inhibitory peptide in in ammatory processes, and its possible role in IBD is discussed.

show abstract

“…[I" 'In] Somatostatin is a tetradecapeptide that has a wide range of biological activities functioning as a hormone releaseinhibitory factor, neurotransmitter, immunomodulator and endogenous inhibitor of cell growth (Mescardo & Sherline, 1982;Reichlin, 1983a,b;Vehmeyer et al, 1986;Malec et al, 1989). Somatostatin acts by binding to specific receptors expressed by target tissues.…”

mentioning

confidence: 99%

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue

O’Byrne

Jt²,

Freyne³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Recent work suggests that between 50 and 75% of small-cell lung cancer (SCLC) tumours have specific high-affinity binding sites for somatostatin. This study evaluated the potential role of the radiolabelled somatostatin analogue, [111In]pentetreotide, in the detection and staging of SCLC in patients prior to and after chemotherapy using scintigraphic imaging techniques. Thirteen patients were studied prior to chemotherapy. Following standard staging six patients had limited stage disease and seven extensive disease. [111In]pentetreotide imaging led to the detection of all primary sites of disease, including a primary site of disease not detectable with chest radiograph or computerised tomography (CT) of the thorax. Five of ten metastatic sites detected by standard staging were also imaged. Furthermore, a cerebellar metastasis was detected in a patient thought to have disease confined to the right hemithorax. This was subsequently confirmed with a CT brain scan. Following chemotherapy [111In]pentetreotide imaging detected residual intrathoracic disease in two of three patients with complete remissions by standard staging and in two patients who had had a partial response to chemotherapy. These results suggest that [111In]pentetreotide imaging may have a role to play in the clinical evaluation of patients with SCLC. Specifically, this technique may be of particular value in detecting residual intrathoracic disease in patients thought to be in complete remission by conventional staging methods. Images Figure 1 Figure 2 Figure 3

show abstract

Short-term somatostatin infusion affects T lymphocyte responsiveness in humans

Cited by 43 publications

References 15 publications

Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets

Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets

Somatostatin in inflammatory bowel disease

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue

Contact Info

Product

Resources

About